Teva Pharmaceutical Industries Ltd (TEVA:TLV) の戦略的SWOT、PESTLE分析、財政インサイト

Report Overview

Report Summary

Teva Pharmaceutical Industries Ltd Strategic SWOT, PESTLE Analysis and Financial Insights – A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends Report is a comprehensive and easily accessible overview of Teva Pharmaceutical Industries Ltd’s business operations. It provides a detailed analysis of the company’s financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company’s performance.

The report begins with in-depth information about Teva Pharmaceutical Industries Ltd including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company’s key attributes.

Next, the report assesses Teva Pharmaceutical Industries Ltd’s strategic standing through various analyses. The ESG spotlight evaluates the company’s environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company’s internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company’s operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Teva Pharmaceutical Industries Ltd’s overall strategic standing and supports informed decision-making and strategic planning.

The report also covers Teva Pharmaceutical Industries Ltd’s financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Teva Pharmaceutical Industries Ltd’s financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors’ operations.

Finally, the report includes recent news and deal activities undertaken by Teva Pharmaceutical Industries Ltd enhancing awareness of the company’s business trends, growth perspectives, and more.

Key Highlights

Teva Pharmaceutical Industries Limited founded in 1901, the company is headquartered in Tel Aviv-Yafo, Tel Aviv District, Israel.operates as a pharmaceutical company that develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products worldwide. Teva Pharmaceutical Industries Limited operates in three key segments: North America, Europe and International Markets. The North America segment covers the United States and Canada markets. The Europe segment includes European Union and non-EU countries. The International Markets segment covers all other global regions. Teva Pharmaceutical Industries Limited offers a broad portfolio of products across almost every major therapeutic area including generics, specialty medicines, over-the-counter products and active pharmaceutical ingredients. Some of the key therapeutic areas include central nervous system, respiratory, oncology, pain management, cardiovascular and anti-infectives. The company has a global infrastructure of manufacturing sites, R&D centers and sales and marketing operations.

Teva Pharmaceutical Industries Ltd in the News:-

2025-06-25 – Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
2025-06-23 – Final Data from Tevas PEARL Real World Study Reinforce the Long term Effectiveness of AJOVY fremanezumab for the Prevention of Chronic and Episodic Migraine Ask ChatGPT
2025-06-03 – Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
2025-05-27 – Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
2025-05-27 – Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

Scope

• Tactical Analysis:- Various strategic frameworks to gain insights into a company’s competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
• Business Strategy:- Contributes to shaping the company’s overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
• Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company’s future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
• Company Fundamentals:- These fundamentals offer valuable insights into the company’s history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
• Competitive Landscape:- An identification of the company’s main competitors, providing insights into the competitive landscape it operates in.

Reasons to Buy

• Comprehensive Understanding of the Teva Pharmaceutical Industries Ltd’s internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
• Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
• Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
• Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
• Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
• Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company Teva Pharmaceutical Industries Ltd:
• Teva Pharmaceutical Industries Ltd Value Chain Analysis
• Teva Pharmaceutical Industries Ltd Porter’s Five Forces Analysis
• Teva Pharmaceutical Industries Ltd VRIO Analysis
• Teva Pharmaceutical Industries Ltd BCG Analysis
• Teva Pharmaceutical Industries Ltd Segmentation, Targeting and Positioning (STP) Analysis
• Teva Pharmaceutical Industries Ltd Ansoff Matrix Analysis

Table of Contents

Table of Contents 2
Tables 6
Charts 7
Teva Pharmaceutical Industries Ltd-Key Company Facts 8
Teva Pharmaceutical Industries Ltd- Company Description 9
Teva Pharmaceutical Industries Ltd- Top Executives 10
Teva Pharmaceutical Industries Ltd- Head Office & Locations 11
Head Office – Country 11
Teva Pharmaceutical Industries Ltd- Products and Services 12
Products 12
Services 14
Teva Pharmaceutical Industries Ltd- Corporate Strategy 15
Teva Pharmaceutical Industries Ltd- Business Description 18
United States Segment 18
Europe 19
International Markets 19
Teva Pharmaceutical Industries Ltd- ESG Spotlight 20
Environment 20
Social 21
Corporate Governance 21
Teva Pharmaceutical Industries Ltd- SWOT Analysis 23
Overview 23
Strengths 25
Weaknesses 28
Opportunities 29
Threats 31
Teva Pharmaceutical Industries Ltd– PESTLE Analysis 33
Overview 33
Political Factors 35
Economic Factors 36
Social Factors 37
Technological Factors 38
Legal Factors 39
Environmental Factors 41
Teva Pharmaceutical Industries Ltd- Financial Deep Dive 42
Share Price Trend – Jan-2024to Jul-2025 (Average Share Closing Price) 42
Profit and Loss Statement 44
Balance Sheet 45
Cash Flow Statement 46
Key Financial Ratio Analysis 47
Teva Pharmaceutical Industries Ltd- Ratio Charts 48
Activity Ratio Charts 48
Growth Ratios Charts 49
Leverage Ratio Charts 50
Liquidity Ratio Charts 51
Profitability Ratio Charts 52
Competing Players 53
Snapshot of Competing Players 54
AstraZeneca Plc 54
Key Company Facts 54
Company Description 54
Bristol-Myers Squibb Company 55
Key Company Facts 55
Company Description 55
Novartis AG 56
Key Company Facts 56
Company Description 56
Pfizer Inc 57
Key Company Facts 57
Company Description 57
Merck & Co., Inc 58
Key Company Facts 58
Company Description 58
Teva Pharmaceutical Industries Ltd – In the News 59
25-Jun-2025 -Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 59
23-Jun-2025 -Final Data from Tevas PEARL Real World Study Reinforce the Long term Effectiveness of AJOVY fremanezumab for the Prevention of Chronic and Episodic Migraine Ask ChatGPT 60
03-Jun-2025 -Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer 61
27-May-2025 -Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA 62
27-May-2025 -Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes 62
27-May-2025 -Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June 63
27-Mar-2025 -Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 64
27-Mar-2025 -Teva Releases Q1 2025 Aide Memoire 64
03-Mar-2025 -Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March 64
25-Feb-2025 -Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder 66
22-Feb-2025 -Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease 67
21-Feb-2025 -Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S 70
18-Feb-2025 -Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn’s and Colitis Organisation (ECCO) 71
18-Feb-2025 -Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept) 72
29-Jan-2025 -Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth 73
Teva Pharmaceutical Industries Ltd- Key Deals 95
10-Jan-2025 – Teva and Samsung Bioepis Enter into a Strategic Partnership for Commercialization of EPYSQLI eculizumab aagh in the United States 95
03-Oct-2024 – Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate 97
30-Apr-2024 – U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira (adalimumab) 98
04-Apr-2024 – US Commercialization Agreement with Quallent to Drive Patient Savings with First High Concentration Citrate Free Interchangeable Biosimilar to Humira adalimumab 100
04-Apr-2024 – Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate 101
01-Apr-2024 – Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement 102
26-Feb-2024 – Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO in China 104
14-Dec-2023 – Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma 105
30-Nov-2023 – Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment 106
13-Nov-2023 – Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program 108
04-Oct-2023 – Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment 110
24-Jul-2023 – Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership 112
12-Jun-2023 – Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims 114
Appendix 115
Definitions 115
SWOT Analysis 115
PESTLE Analysis 115
Value Chain Analysis 115
ESG Spotlight 115
Financial Deep Dive 115
Financial Ratios- 116
Activity Ratios 116
Growth Ratios 117
Leverage Ratios 118
Liquidity Ratios 119
Market Ratios 120
Profitability Ratios 120
Research Methodology 121
Disclaimer 122
Contact Us 122

Table 1: Teva Pharmaceutical Industries Ltd – Company Facts 8
Table 2: Teva Pharmaceutical Industries Ltd – Digital Presence 8
Table 3: Teva Pharmaceutical Industries Ltd- Top Executives 10
Table 4: Teva Pharmaceutical Industries Ltd- Products 12
Table 5: Teva Pharmaceutical Industries Ltd-Services 14
Table 6: Teva Pharmaceutical Industries Ltd – Share Price Trend – Jan-2024to Jul-2025 42
Table 7: Teva Pharmaceutical Industries Ltd- Ratio Analysis -2021-2024 47
Table 8: Teva Pharmaceutical Industries Ltd -Competing Players 53
Table 9: Competing Players – AstraZeneca Plc – Key Company Facts 54
Table 10: Competing Players – Bristol-Myers Squibb Company – Key Company Facts 55
Table 11: Competing Players – Novartis AG – Key Company Facts 56
Table 12: Competing Players – Pfizer Inc. – Key Company Facts 57
Table 13: Competing Players – Merck & Co., Inc. – Key Company Facts 58

Figure 1: Teva Pharmaceutical Industries Ltd- SWOT Analysis 24
Figure 2: Teva Pharmaceutical Industries Ltd-PESTLE Analysis 34
Figure 3: Teva Pharmaceutical Industries Ltd-Average Share Price Trend – Jan-2024to Jul-2025 43
Figure 4: Teva Pharmaceutical Industries Ltd- Profit and Loss Statement -2021-2024 44
Figure 5: Teva Pharmaceutical Industries Ltd- Balance Sheet-2021-2024 45
Figure 6: Teva Pharmaceutical Industries Ltd- Cash Flow Statement 2021-2024 46
Figure 7: Teva Pharmaceutical Industries Ltd- Activity Ratio Charts 48
Figure 8: Teva Pharmaceutical Industries Ltd- Growth Ratio Charts (Value %) 49
Figure 9: Teva Pharmaceutical Industries Ltd- Leverage Ratio Charts 50
Figure 10: Teva Pharmaceutical Industries Ltd- Liquidity Ratio Charts 51
Figure 11: Teva Pharmaceutical Industries Ltd- Profitability Ratio Charts (Value %) 52

Quaintel Research（クアインテルリサーチ）は200セクター超における世界の企業の競合ベンチマーキング、販売情報、投資魅力度、イノベーションについてデータ駆動型の実用的な情報を提供する専門調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業同一住所内人数無制限でレポートファイルのご共有が可能です。
  • エンタープライズライセンス
    • 同一企業であれば、人数無制限でレポートファイルの閲ご共有が可能です。
• 納期
  • ご注文後2-3営業日以内
• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

最新調査レポート

• Benteler International AGの戦略的SWOTインサイト 2025-04-30
• Schauinsland-Reisen GmbHの戦略的SWOTインサイト 2025-04-30
• Seat, S.A.の戦略的SWOTインサイト 2025-04-30
• Havas N.A.の戦略的SWOTインサイト 2025-04-30
• TelevisaUnivision Incの戦略的SWOTインサイト 2025-04-30

Quaintel Research 出版レポート一覧

Quaintel Research出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。